Work

362 POSTER A phase 2 trial of AP23573, an mTOR inhibitor, in patients (pts) with taxane-resistant androgen-independent prostate cancer (AIPC)

Year: 2006

Type: conference-abstract

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(06)70367-6

Authors: M.E. Gross, R.J. Amato, M. Mushtaq, G. Wilding, G. Bubley

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1991674492

Cites:

Cited by:

Related to: 10